Department of Health and Human Services
National Institutes of Health
Toggle navigation
Search
Home
About the Clinical Center
Clinical Trials & You
Participate in a Study
Referring a Patient
How to Search
Contact Us
Search the Studies
Go Back
Searched Result
250 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Please note that only the first 5 legal search words are being processed.
Protocol Number
Title
Protocol Status
Min-Max Age
Institute
Keywords
000491-C
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
Participants currently recruited/enrolled
18-125 Years
NCI
Large Carcinoma
000045-C
A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and other KK-LC-1 Positive Epithelial Cancers
Participants currently recruited/enrolled
18-120 Years
NCI
Large Carcinoma
19-C-0016
Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors
Participants currently recruited/enrolled
0-125 Years
NCI
Carcinoma Rhabdoid
18-C-0147
Phase 1 with Expansion Cohorts in a Study of NEO-201 In Adults with Chemo-Resistant Solid Tumors
Participants currently recruited/enrolled
18-125 Years
NCI
Large Carcinoma
17-C-0092
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Large Carcinoma
16-C-0154
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Large Carcinoma
14-C-0104
A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived from Patients with Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen
Participants currently recruited/enrolled
18-70 Years
NCI
Large Carcinoma
13-C-0152
A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults with Refractory Solid Tumors
Completed Study; data analyses ongoing
2-29 Years
NCI
Large Phenotype
10-C-0166
A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab
Participants currently recruited/enrolled
18-72 Years
NCI
Large Carcinoma
09-C-0161
Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
Enrolling by Invitation
18-125 Years
NCI
Large Carcinoma
04-HG-0127
Clinical and Basic Investigations of Methylmalonic Acidemia (MMA) and Related Disorders
Participants currently recruited/enrolled
0-125 Years
NHGRI
Large Phenotype
01-N-0206
Phenotype/Genotype Correlations in Movement Disorders
Participants currently recruited/enrolled
2-125 Years
NINDS
Large Phenotype
94-HG-0132
The Phenotype and Etiology of Proteus Syndrome
Participants currently recruited/enrolled
0-125 Years
NHGRI
Large Phenotype
89-C-0086
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
Participants currently recruited/enrolled
2-125 Years
NCI
Carcinoma Phenotype
001125-DK
Optimizing HBV Care Cascade among Foreign-Born in the United States (FOCUS-HBV Study)
Participants currently recruited/enrolled
18-100 Years
NIDDK
Large
001109-C
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Participants currently recruited/enrolled
8-125 Years
NCI
Carcinoma
001099-C
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-Fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
001032-C
BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (
Recruitment has not started
18-125 Years
NCI
Carcinoma
001018-CH
Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C
Participants currently recruited/enrolled
0-125 Years
NICHD
Large
001004-C
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon Oncosignature (R) Status
Participants currently recruited/enrolled
18-120 Years
NCI
Carcinoma
000930-C
A Phase 1b/2 Study of HCW9218, a Bifunctional TGF-Beta Antagonist/IL-15 Protein Complex, for Advanced Pancreatic Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000826-C
An Open Label, Randomised, Phase 2 Study to Evaluate the Safety and Efficacy of MTL-CEBPA Administered in Combination with Sorafenib or Sorafenib Alone, in TKI Naive Participants with Previously Treated Advanced Hepatocellular Carcinoma (HCC) and Hepatit
Recruitment has not started
18-125 Years
NCI
Carcinoma
000782-C
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
Recruitment has not started
18-125 Years
NCI
Carcinoma
000736-CC
Imaging Characterization of the Biomechanical Coupling of Brain and Skull: An Observational Study
Participants currently recruited/enrolled
21-65 Years
CC
Large
000732-C
A Long-Term Follow-Up Study of Patients Who Received VOR33
Recruitment has not started
18-125 Years
NCI
Large
000666-C
A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Recruitment has not started
18-125 Years
NCI
Carcinoma
000633-C
Phase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Large
000596-C
Phase II Study of Olaparib in Subjects with Advanced Pancreatic Acinar Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000580-C
A Phase 1/2, Open Label Dose-Escalation and Expansion Trial of Nkt2152, an Orally Administered Hif2a Inhibitor, to Investigate Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000556-H
NHLBI-Emory Advanced Cardiac CT Reconstruction
Recruitment has not started
18-125 Years
NHLBI
Large
000539-H
Addition of JSP191 (c-kit antibody) to Non-myeloablative Hematopoietic Cell Transplantation For Sickle Cell Disease and Beta-Thalassemia
Participants currently recruited/enrolled
4-100 Years
NHLBI
Large
000520-C
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG with or without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Recruitment has not started
18-125 Years
NCI
Carcinoma
000518-CC
Observational Study of Dietary Intake and Dietary Behaviors in Adults with Sickle Cell Disease
Participants currently recruited/enrolled
18-125 Years
CC
Phenotype
000516-C
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma involving the Central Nervous System
Participants currently recruited/enrolled
18-125 Years
NCI
Large
000494-DK
Natural History of Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
Participants currently recruited/enrolled
18-125 Years
NIDDK
Large
000486-C
A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination with Cisplatin and with Cisplatin Plus Gemcitabine in Advanced Solid Tumors with an Emphasis on Urothelial Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000479-H
Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies
Participants currently recruited/enrolled
18-125 Years
NHLBI
Phenotype
000473-C
A Randomized Phase II Study of Systemic Chemotherapy with or without HAI FUDR-Dexamethasone in Patients with Unresectable Intrahepatic Cholangiocarcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000462-C
Phase 2, Open-label, Single-arm, Window of Opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients With Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000417-CC
Characterization of the Nociception Phenotype in Individuals with Intellectual Disability
Clinical hold/Recruitment or enrollment suspended
8-30 Years
CC
Phenotype
000413-H
Natural History study of CADASIL
Participants currently recruited/enrolled
18-100 Years
NHLBI
Phenotype
000393-DK
Diabetic Kidney Disease and Related Complications in American Indians with Type 2 Diabetes
Participants currently recruited/enrolled
18-125 Years
NIDDK
Phenotype
000387-H
The Natural History of Acquired and Inherited Bone Marrow Failure Syndromes.
Participants currently recruited/enrolled
2-125 Years
NHLBI
Large
000354-C
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000326-H
A Phase 1, Dose Escalation, Safety and Tolerability Study of NX- 2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
Participants currently recruited/enrolled
18-125 Years
NHLBI
Large
000324-C
Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-35 Years
NCI
Large
000317-C
A Phase II, Open-Label Trial of PT-112 in Subjects with Thymoma and Thymic Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000302-C
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000299-H
Technical Development of Cardiovascular MRI
Participants currently recruited/enrolled
18-125 Years
NHLBI
Large
000274-C
Phase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Participants currently recruited/enrolled
18-125 Years
NCI
Large
000254-C
A Phase II Trial of the Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000237-C
Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis from Colorectal, Appendiceal, Small Bowel, Gastric, Ovarian, or Other Gynecologic Primary Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000213-HG
Clinical and Laboratory Study of Rare Skeletal Disorders
Participants currently recruited/enrolled
0-125 Years
NHGRI
Large
000193-C
Phase 1 Study of Copanlisib with Dose-adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and other High-Grade B-cell Lymphomas
Clinical hold/Recruitment or enrollment suspended
18-125 Years
NCI
Large
000186-I
Part B- Phase I/II, Non-randomized, Multicenter, Open-label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients with X-Linked Chronic Granulomatous Disease
Clinical hold/Recruitment or enrollment suspended
3-12 Years
NIAID
Large
000137-CH
Implications of Maternal 45,X Mosaicism As A Secondary Genomic Finding Following Cell-free DNA Sequencing During Pregnancy: A Deep Phenotype Study
Recruitment has not started
18-99 Years
NICHD
Phenotype
000130-DK
Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
Participants currently recruited/enrolled
18-125 Years
NIDDK
Large
000124-C
A Phase 2 Study of the MEK inhibitor Trametinib (IND #119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Recruitment has not started
2-21 Years
NCI
Large
000108-EI
An Observational Prospective Natural History Study of Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4
Participants currently recruited/enrolled
10-125 Years
NEI
Large
000096-C
A Phase II study of Immunotherapy Combination: Irradiated PD-L1 CAR-NK cells plus Pembrolizumab plus N-803 for Subjects with Recurrent/Metastatic Gastric or Head and Neck Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Large
000080-C
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000079-DK
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
Participants currently recruited/enrolled
18-125 Years
NIDDK
Large
000077-DC
Collection of Clinical Data and Specimens for Research on Head and Neck and Communication Disorders
Participants currently recruited/enrolled
2-125 Years
NIDCD
Carcinoma
22-C-0005
Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
22-C-0004
A Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer
Participants currently recruited/enrolled
12-125 Years
NCI
Carcinoma
21-I-0029
Natural history, epidemiology and pathogenesis of severe HPV-related diseases (Neptune)
Participants currently recruited/enrolled
3-125 Years
NIAID
Large
21-DC-0002
Phase III Interventional Study using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss among Individuals with Head and Neck Cancer
Recruitment has not started
18-125 Years
NIDCD
Carcinoma
21-C-0030
Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
21-C-0023
A Phase I Study of Pomalidomide and Nivolumab in Patients with Virus-Associated Malignancies With or Without HIV
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
21-C-0021
SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging
Participants currently recruited/enrolled
6-125 Years
NCI
Large
21-C-0019
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients with Relapsed/Refractory Hairy Cell Leukemia and Variant
Participants currently recruited/enrolled
18-125 Years
NCI
Large
21-C-0014
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Large
21-C-0012
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis from Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
21-C-0011
A Phase I/II Study of the Cyclin-Dependent Kinase(CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type 1 (NF1) Related Atypical Neurofibromas
Participants currently recruited/enrolled
12-125 Years
NCI
Large
20-NR-0124
Development of Immersive VR Environments to Induce and Evaluate Cognitive Fatigability: User Experience and Healthy Control Studies
No longer recruiting/follow-up only
18-75 Years
NINR
Large
20-I-0084
Sample Collection for Systems Evaluation of Patients with Unknown or Incompletely Characterized Immune Defects
Participants currently recruited/enrolled
2-125 Years
NIAID
Phenotype
20-HG-0120
Acute Infection in Mitochondrial Disease: An Observational Prospective Natural History Study of Metabolism, Infection and Immunity During the COVID19 Pandemic
Participants currently recruited/enrolled
0-125 Years
NHGRI
Phenotype
20-HG-0090
Genetics of COVID-19 Susceptibility and Manifestations
Clinical hold/Recruitment or enrollment suspended
0-125 Years
NHGRI
Large
20-EI-0163
Oral Metformin for Treatment of ABCA4 Retinopathy
Participants currently recruited/enrolled
12-125 Years
NEI
Large
20-CH-0165
Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals with Androgen Insensitivity
Participants currently recruited/enrolled
0-99 Years
NICHD
Phenotype
20-CH-0126
Data Collection Study of Pediatric and Adolescent Gynecology Conditions
Participants currently recruited/enrolled
0-125 Years
NICHD
Large
20-CC-0039
A Feasibility Study to Evaluate the Combination of Electromagnetic Tracking and Optical Imaging with Indocyanine Green (ICG) for Hepatic Biopsies
Enrolling by Invitation
18-125 Years
CC
Carcinoma
20-C-0152
Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
20-C-0149
Phase II Trial of Olaparib (LYNPARZA) plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas that Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
20-C-0142
A Phase II Study of Bintrafusp alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects with Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
20-C-0098
A Phase 1/2, Open Label, Dose-Escalation, Safety and Tolerability Study of NC410 in Subjects with Advanced or Metastatic Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
20-C-0097
A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects with Thymoma and Thymic Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
20-C-0024
A Sequential Window of Opportunity Trial of Anti-PD-L1/TGF-beta trap (M7824 ) Alone and in Combination with TriAd Vaccine, and N-803 for Resectable Head and Neck Squamous Cell Carcinoma not Associated with Human Papillomavirus Infection.
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
20-C-0022
Phase II trial of VB-111 in Combination with Nivolumab in Patients with Metastatic Colorectal Cancer (mCRC)
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
20-C-0013
Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
20-C-0012
A Phase I Study of Bintrafusp alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination with Stereotactic Body Radiation Therapy (SBRT) in Adults with Metastatic Non-Prostate Genitourinary Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
20-C-0009
Randomized Phase II Trial of Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
20-C-0006
A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
19-M-0054
Mapping the Phenotype in Adults with Phelan-McDermid Syndrome
Completed Study; data analyses ongoing
0-125 Years
NIMH
Phenotype
19-HG-0059
Longitudinal Studies of Patients with FPDMM
Participants currently recruited/enrolled
0-125 Years
NHGRI
Large
19-C-0137
A Phase II Study of Ipilimumab, Cabozantinib, and NIvolumab in Rare Genitourinary Cancers (ICONIC)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
19-C-0134
A Phase 1/1b Study of Enhancement of Immune Reconstitution and Vaccine Responses with Administration of Recombinant Human IL-7-hyFc (NT-I7) in Older Subjects Following Chemotherapy
Participants currently recruited/enrolled
60-125 Years
NCI
Carcinoma
19-C-0129
A Phase II Study of Intraperitoneal and Intravenous Paclitaxel Chemotherapy with Oral Capecitabine for Gastric Adenocarcinoma with Peritoneal Carcinomatosis
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
19-C-0117
A Phase 1 / 2 Single Arm Open-label Clinical Trial of Gavocabtagene Autoleucel (gavo-cel) in Patients with Advanced Mesothelin Expressing Cancer
Participants currently recruited/enrolled
18-120 Years
NCI
Large
19-C-0116
A Phase 2 Study of Acalabrutinib with DA-EPOCH-R or R-CHOP for Patients with Untreated Diffuse Large B-cell Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Large
19-C-0103
A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas with Secondary Involvement of the Central Nervous System (CNS)
Participants currently recruited/enrolled
18-125 Years
NCI
Large
19-C-0094
A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
19-C-0076
A Phase 1 Study of Interleukin-15 in Combination with Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Completed Study; data analyses ongoing
18-125 Years
NCI
Large
19-C-0041
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
19-C-0039
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
19-C-0033
Phase II Study of Nivolumab (anti-PD1), Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic Cancers
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
19-C-0023
A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and other genitourinary tumors with DNA-Repair Defects
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
19-C-0017
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Participants currently recruited/enrolled
18-70 Years
NCI
Large
19-C-0006
Phase II Trial Evaluating Nivolumab In Patients With IDH-Mutant Gliomas With And Without Hypermutator Phenotype
Participants currently recruited/enrolled
18-125 Years
NCI
Phenotype
18-N-0133
Feasibility of Endosphenoidal Coil Placement for Imaging of the Sella During Transsphenoidal Surgery
Participants currently recruited/enrolled
18-125 Years
NINDS
Large
18-I-0105
VRC 609: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously with or without Recombinant Human Hyaluronidase PH20 (rHuPH2
Completed Study; data analyses ongoing
18-50 Years
NIAID
Large
18-HG-0129
Reverse Phenotyping Core (RPC)
Enrolling by Invitation
4-125 Years
NHGRI
Phenotype
18-H-0118
Technical and Translational Development of Cardiovascular MRI (CMR)
Participants currently recruited/enrolled
7-125 Years
NHLBI
Large
18-H-0108
Vascular Disease Discovery Protocol
Participants currently recruited/enrolled
2-100 Years
NHLBI
Phenotype
18-H-0012
A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients with Metastatic Clear Cell Renal Cell Carcinoma
Participants currently recruited/enrolled
18-75 Years
NHLBI
Carcinoma
18-H-0011
Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System
Participants currently recruited/enrolled
18-125 Years
NHLBI
Large
18-DK-0091
Long-Term Follow-Up Of Subjects With CHC Who Achieved A Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
Participants currently recruited/enrolled
18-125 Years
NIDDK
Carcinoma
18-C-0138
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma.
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
18-C-0125
A Phase I Clinical Trial of T cells Expressing a Novel Fully-human Anti-BCMA CAR for Treating Multiple Myeloma
No longer recruiting/follow-up only
18-73 Years
NCI
Large
18-C-0110
Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
18-C-0062
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Completed Study; data analyses ongoing
2-30 Years
NCI
Carcinoma
18-C-0059
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-39 Years
NCI
Large
18-C-0034
A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
18-C-0024
A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy with Floxuridine and Dexamethasone in Combination with Systemic Chemotherapy for Patients with Colorectal Cancer Metastatic to the Liver
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
18-C-0008
Phase III Randomized Adjuvant study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) versus Observation
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
17-H-0124
Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients Using Plerixafor
Completed Study; data analyses ongoing
18-125 Years
NHLBI
Large
17-H-0069
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
Participants currently recruited/enrolled
2-125 Years
NHLBI
Large
17-DC-0138
Observational Study of Hearing Loss and the Effects of Statin Drugs in Head and Neck Squamous Cell Carcinoma Patients Treated with Cisplatin Chemoradiation
Completed Study; data analyses ongoing
18-125 Years
NIDCD
Carcinoma
17-CH-0020
Observational Study of Males with Creatine Transporter Deficiency (CTD)
No longer recruiting/follow-up only
2-40 Years
NICHD
Large
17-C-0164
A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
No longer recruiting/follow-up only
18-125 Years
NCI
Large
17-C-0157
A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (oportuzumab monatox, VB4-845) in Subjects with High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated with Bacillus Calmette-Gu(SqrRoot)(Copyright)rin (BCG)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
17-C-0149
Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL),and Other Extranodal Diffuse Large B-cell Lymphomas
No longer recruiting/follow-up only
18-125 Years
NCI
Large
17-C-0140
Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural Mesotheliomas
Completed Study; data analyses ongoing
18-99 Years
NCI
Carcinoma
17-C-0137
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
Enrolling by Invitation
3-65 Years
NCI
Large
17-C-0127
Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Large
17-C-0117
A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of PEN-866 in Advanced Solid Malignancies
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
17-C-0086
An Open-label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
17-C-0066
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma after Progression on Platinum-Based Chemotherapy
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
17-C-0048
Anti-CD30 CAR T Cells with Fully-human Binding Domains for Treating CD30-expressing Lymphomas Including Anaplastic Large Cell Lymphomas
Completed Study; data analyses ongoing
18-73 Years
NCI
Large
17-C-0011
Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
17-C-0007
Phase I/II Study of PROSTVAC in Combination with Nivolumab in Men with Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Large
16-H-0132
CADASIL Disease Discovery
Completed Study; data analyses ongoing
18-100 Years
NHLBI
Phenotype
16-DK-0068
The Molecular, Cellular, and Genetic Characterization of Human Adipose Tissue and its Role in Metabolism
Participants currently recruited/enrolled
18-125 Years
NIDDK
Phenotype
16-C-0171
Phase I/II Study of Lenalidomide Combined with Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Large
16-C-0135
A Pilot Study of Combined Immune Checkpoint Inhibition in combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
16-C-0128
A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
16-C-0121
A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
16-C-0107
A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
16-C-0076
Prospective Screening for Patient Specific Genotypes and Phenotypes that Influence Drug Dosing and Trial Selection in Cancer Patients
Enrolling by Invitation
18-125 Years
NCI
Phenotype
16-C-0043
Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
No longer recruiting/follow-up only
18-125 Years
NCI
Large
16-AT-0077
Clinical and Scientific Assessment of Pain and Painful Disorders
Participants currently recruited/enrolled
12-125 Years
NCCIH
Phenotype
15-M-0139
Mapping the Genotype, Phenotype, and Natural History of Phelan McDermid Syndrome
Participants currently recruited/enrolled
1-125 Years
NIMH
Phenotype
15-I-0056
Collection of Plasma from Subjects that Recovered From or Were Vaccinated To Emerging Infectious Diseases
Enrolling by Invitation
18-70 Years
NIAID
Large
15-C-0160
A Phase I Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
15-C-0157
Phase I/II Trial of Vandetanib in Combination with Metformin in Subjects with HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
15-C-0150
A Phase I/II Trial of Topotecan with VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
15-C-0099
A Phase 1, Open-Label, Dose-Escalation Study of SNX-5422 and Everolimus in Subjects with Neuroendocrine Tumors
Completed Study; data analyses ongoing
18-100 Years
NCI
Carcinoma
15-C-0078
Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
No longer recruiting/follow-up only
18-65 Years
NCI
Large
15-C-0029
Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-39 Years
NCI
Large
15-AR-0144
Studies of Dermatologic Diseases-Biospecimen Acquisition Protocol
Participants currently recruited/enrolled
2-125 Years
NIAMS
Carcinoma
15-AG-0063
The Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT)
Participants currently recruited/enrolled
20-125 Years
NIA
Phenotype
14-HG-0048
Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST)
Participants currently recruited/enrolled
21-125 Years
NHGRI
Phenotype
14-H-0188
Prospective Evaluation of Next Generation CT Reconstruction
Participants currently recruited/enrolled
18-99 Years
NHLBI
Large
14-H-0155
A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease
No longer recruiting/follow-up only
18-50 Years
NHLBI
Large
14-H-0077
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia in Individuals with Higher Risk of Transplant Failure
Participants currently recruited/enrolled
4-125 Years
NHLBI
Large
14-C-0157
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Large
14-C-0128
Collection of Pharmacokinetic Samples from Patients with Unanticipated Response, Significant Toxicity or Concern of Future Toxicity
Enrolling by Invitation
2-125 Years
NCI
Large
14-C-0052
A Phase I/II Study of the Treatment of Metastatic Cancer that Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and Aldesleukin
Completed Study; data analyses ongoing
18-70 Years
NCI
Large
14-C-0037
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
14-C-0022
A Phase II Study for Metastatic Melanoma Using High-Dose Chemotherapy Preparative Regimen Followed by Cell Transfer Therapy Using Tumor-Infiltrating Lymphocytes Plus IL-2 with the Administration of Pembrolizumab in the Retreatment Arm
Completed Study; data analyses ongoing
18-70 Years
NCI
Large
14-C-0015
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
14-AA-0181
NIAAA Natural History Protocol
Participants currently recruited/enrolled
18-100 Years
NIAAA
Phenotype
14-AA-0080
Characterization Imaging Instruments for Addiction Neuroimaging Assessments
Participants currently recruited/enrolled
18-125 Years
NIAAA
Phenotype
14-AA-0066
Behavioral and Functional Task Development, Implementation, and Testing
Participants currently recruited/enrolled
18-65 Years
NIAAA
Phenotype
13-H-0194
Inflammatory Characterization of Known or Possible Cardiovascular Diseases
No longer recruiting/follow-up only
18-125 Years
NHLBI
Large
13-C-0202
Tissue Procurement and Natural History Study of Patients with Malignant Mesothelioma and Other Mesothelin Expressing Cancers
Participants currently recruited/enrolled
2-125 Years
NCI
Large
13-C-0118
A Phase I/II Trial of TRC102 (methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and Lymphomas
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
12-EI-0042
NEI Intramural Biorepository for Retinal Diseases
Participants currently recruited/enrolled
2-125 Years
NEI
Phenotype
12-C-0205
A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
12-C-0178
Longitudinal Assessment and Natural History Study of Children and Adults with MEN2A or MEN2B with or without Medullary Thyroid Carcinoma
Participants currently recruited/enrolled
0-125 Years
NCI
Carcinoma
12-C-0175
Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets
Completed Study; data analyses ongoing
18-125 Years
NCI
Large
12-C-0118
A Phase II Study of Sunitinib in Patients with Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma with at Least One Prior Line of Platinum-Based Systemic Chemotherapy
No longer recruiting/follow-up only
18-100 Years
NCI
Carcinoma
12-C-0112
Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults with B Cell Malignancies
Completed Study; data analyses ongoing
1-30 Years
NCI
Large
11-M-0251
A Longitudinal Investigation of the Endocrine and Neurobiologic Events Accompanying Puberty
Participants currently recruited/enrolled
7-35 Years
NIMH
Large
11-CC-0152
The Natural History of Liver Disease in a Cohort of Participants with Hepatitis B and/or Hepatitis C with or without HIV Infection
Completed Study; data analyses ongoing
18-99 Years
CC
Carcinoma
11-C-0161
A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; Hydrogen Sulfate in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
No longer recruiting/follow-up only
2-18 Years
NCI
Large
11-C-0140
A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
11-C-0123
A Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor-Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction with
No longer recruiting/follow-up only
18-66 Years
NCI
Large
11-C-0096
Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
10-M-0112
Defining the Brain Phenotype of Children with Williams Syndrome
Participants currently recruited/enrolled
5-125 Years
NIMH
Phenotype
10-EI-0140
Genotype - phenotype Study of Patients with Plaquenil-induced Retinal Toxicity
Participants currently recruited/enrolled
18-125 Years
NEI
Phenotype
10-DK-N091
Molecular and Clinical Profile of Diabetes Mellitus and its Complications
Participants currently recruited/enrolled
18-125 Years
NIDDK
Large
10-DA-N457
Characterization of Phenotypic and Genotypic Regressors
Participants currently recruited/enrolled
18-125 Years
NIDA
Phenotype
10-C-0114
A Phase II Study of Bevacizumab and Erlotinib in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
10-C-0011
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Completed Study; data analyses ongoing
18-125 Years
NCI
Large
09-I-0184
Studies in the Pathogenesis of Systemic Capillary Leak Syndrome
Participants currently recruited/enrolled
0-125 Years
NIAID
Large
08-H-0186
Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity with Bortezomib
Completed Study; data analyses ongoing
18-70 Years
NHLBI
Carcinoma
08-H-0046
Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated with Severe Neutropenia Refractory to Immunosuppressive Therapy
Completed Study; data analyses ongoing
4-75 Years
NHLBI
Large
07-HG-0002
ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study
No longer recruiting/follow-up only
6-95 Years
NHGRI
Large
07-DK-0077
Study of the Phenotype of Overweight and Obese Adults
Participants currently recruited/enrolled
18-100 Years
NIDDK
Phenotype
07-C-0121
Phase 2 Study of the C-Met RTK Inhibitor Foretinib (Formerly GSK 1363089) in Subjects with Papillary Renal Cell Carcinoma (PRC)
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
06-H-0190
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders with Alemtuzumab (Campath)
Completed Study; data analyses ongoing
18-85 Years
NHLBI
Large
06-EI-0236
National Ophthalmic Genotyping and Phenotyping Network Stage 1 - Creation of DNA Repository for Inherited Ophthalmic Diseases
No longer recruiting/follow-up only
2-125 Years
NEI
Phenotype
05-CC-0091
Electromagnetic Tracking of Devices During Interventional Procedures
Enrolling by Invitation
18-125 Years
CC
Carcinoma
05-C-0252
Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated de Novo Diffuse Large B-Cell Lymphomas
Completed Study; data analyses ongoing
18-125 Years
NCI
Large
05-C-0152
Variation in Gene Expression in Neurofibromatosis Type 1
Completed Study; data analyses ongoing
2-100 Years
NCI
Phenotype
04-H-0012
Collection of Blood, Bone Marrow, Urine, and/or Tissue Samples from Patients with Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family Members
Participants currently recruited/enrolled
2-125 Years
NHLBI
Large
04-E-0053
Personalized Environment and Genes Study
Participants currently recruited/enrolled
18-130 Years
NIEHS
Phenotype
04-CC-0046
Citrate Effects and Bone Density Studies in Long-Term Apheresis Donors
Completed Study; data analyses ongoing
18-80 Years
CC
Large
04-C-0238
A Phase 2 Study of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Von Hippel Lindau Disease and Renal Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Large
04-AR-0205
Progression of Spinal Fusion in Ankylosing Spondylitis
Completed Study; data analyses ongoing
18-125 Years
NIAMS
Large
03-I-0263
VRC 200: A Multicenter Specimen Collection Protocol to Obtain Human Biological Samples for Research Studies
Participants currently recruited/enrolled
18-125 Years
NIAID
Large
03-H-0282
Characterization of Cardiac Function in Subjects with Hereditary Hemochromatosis Who Are New York Heart Association Functional Class I
Completed Study; data analyses ongoing
21-100 Years
NHLBI
Large
03-EI-0033
X-Linked Juvenile Retinoschisis - Clinical and Molecular Studies
Participants currently recruited/enrolled
0-125 Years
NEI
Large
03-C-0277
Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols
Enrolling by Invitation
18-125 Years
NCI
Large
03-AR-0173
Studies of Natural History, Pathogenesis, and Outcomes in Autoimmune and Inflammatory Diseases Including Juvenile Dermatomyositis
Participants currently recruited/enrolled
2-125 Years
NIAMS
Phenotype
02-I-0086
Evaluation of Viral Factors and Immune Parameters to Study HIV-Specific Immunity
Participants currently recruited/enrolled
18-125 Years
NIAID
Large
02-I-0055
Evaluation, Treatment, and Follow-up of Patients with Lyme Disease
Participants currently recruited/enrolled
2-125 Years
NIAID
Large
02-H-0250
A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning with Campath-1H
Completed Study; data analyses ongoing
18-125 Years
NHLBI
Large
02-DK-0022
Long-Term Efficacy of Leptin Replacement in Treatment of Lipodystrophy
Completed Study; data analyses ongoing
1-125 Years
NIDDK
Large
02-C-0313
Cancer Risk in Xeroderma Pigmentosum Heterozygotes
Participants currently recruited/enrolled
0-99 Years
NCI
Carcinoma
02-C-0211
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
Participants currently recruited/enrolled
2-125 Years
NCI
Large
02-C-0064
Collection of Peripheral Blood and/or Urine From Patients Undergoing Radiation Therapy
Enrolling by Invitation
18-125 Years
NCI
Carcinoma
02-C-0052
Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study
Participants currently recruited/enrolled
0-125 Years
NCI
Phenotype
01-M-0232
Positron Emission Tomography (PET) Scanning in Dopamine Disorders: Parkinson's Disease and Schizophrenia
Participants currently recruited/enrolled
18-90 Years
NIMH
Phenotype
01-I-0238
Host Response to Infection and Treatment in Leishmania Infection of Humans
Participants currently recruited/enrolled
3-100 Years
NIAID
Large
01-I-0202
Natural History, Genetics, Phenotype, and Treatment of Mycobacterial Infections
Participants currently recruited/enrolled
0-100 Years
NIAID
Phenotype
01-HG-0109
Natural History Study of the Clinical and Molecular Manifestations of Smith-Magenis Syndrome (SMS)
No longer recruiting/follow-up only
0-125 Years
NHGRI
Phenotype
01-DC-0229
Genetic Analysis of Hereditary Disorders of Hearing and Balance
Completed Study; data analyses ongoing
0-99 Years
NIDCD
Phenotype
01-C-0030
Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
No longer recruiting/follow-up only
18-125 Years
NCI
Large
00-I-0159
Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)
Participants currently recruited/enrolled
0-125 Years
NIAID
Phenotype
00-C-0078
Collection of Blood, Fluid, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer or Normal Volunteers
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
99-C-0128
Evaluation for NCI Surgery Branch Clinical Research Protocols
Participants currently recruited/enrolled
18-125 Years
NCI
Large
97-HG-0192
Genetic Studies in the Amish and Mennonites
Completed Study; data analyses ongoing
18-125 Years
NHGRI
Large
97-DC-0057
Genetic Studies of Stuttering
Completed Study; data analyses ongoing
6-125 Years
NIDCD
Large
97-CH-0076
A Clinical and Genetic Investigation of Pituitary and HYPOTHALAMIC Tumors and Related Disorders
Participants currently recruited/enrolled
3-70 Years
NICHD
Large
96-I-0052
A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients with Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations
Participants currently recruited/enrolled
13-125 Years
NIAID
Large
95-M-0150
A Neurobiological Investigation of Patients with Schizophrenia Spectrum Disorders and Their Siblings
Participants currently recruited/enrolled
18-55 Years
NIMH
Large
95-I-0027
Virologic and Immunologic Evaluation of Lymph Node, Tonsillar and Intestinal Biopsies, and Bronchoalveolar Lavage Fluid
Participants currently recruited/enrolled
18-125 Years
NIAID
Large
95-CH-0059
Definition of the Genotype and Clinical Phenotype of Primary Pigmented Nodular Adrenocortical Disease (PPNAD), Carney Complex, Peutz-Jeghers Syndrome and Related Conditions
Completed Study; data analyses ongoing
3-70 Years
NICHD
Phenotype
94-I-0079
Eosinophil Activation and Function in Parasitic Infections and Other Conditions with Increased Tissue or Peripheral Blood Eosinophilia in Humans
Participants currently recruited/enrolled
1-100 Years
NIAID
Large
94-HG-0105
An Exploratory Study of the Genetics, Pathophysiology, and Natural History of Autoinflammatory Diseases
Participants currently recruited/enrolled
0-125 Years
NHGRI
Large
93-I-0063
Study of the Immunopathogenesis, Natural History, and Genetics of Autoimmune Lymphoproliferative Syndrome (ALPS) Associated with an Expansion of CD4-8-/TCR alpha/beta+ T Cells
Participants currently recruited/enrolled
0-99 Years
NIAID
Large
93-C-0133
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children with Previously Untreated Patients with Aggressive Non-Hodgkin's Lymphoma
No longer recruiting/follow-up only
12-125 Years
NCI
Large
89-I-0158
Studies of Immune Regulation in Patients with Common Variable Immunodeficiency and Related Humoral Immunodeficiency Syndromes
Participants currently recruited/enrolled
2-125 Years
NIAID
Large
87-DK-0029
Diagnosis and Treatment of Patients with Cystic Fibrosis
Participants currently recruited/enrolled
4-125 Years
NIDDK
Phenotype
86-HG-0096
Studies of Genetic Heterogeneity in Patients with Lysosomal Storage Disorders
Enrolling by Invitation
0-125 Years
NHGRI
Phenotype
82-I-0183
A Natural History Study of the Immune Regulation of Idiopathic Inflammatory Bowel Diseases: Crohn's Disease, Ulcerative Colitis, and Other Inflammatory Conditions of the Gut
Participants currently recruited/enrolled
0-75 Years
NIAID
Large
81-I-0164
Procedures to Obtain Plasma, Lymphocytes, or Other Specimens for Research Studies
Participants currently recruited/enrolled
18-125 Years
NIAID
Large
79-C-0111
The Treatment of Stage I and II Carcinoma of the Breast with Mastectomy and Axillary Dissection vs. Excisional Biopsy Axillary Dissection, and Definitive Irradiation
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma